Outcome of allogeneic stem cell transplantation in patients older than 50 years of age

Satoru Takada, Shinichiro Okamoto, Hisashi Sakamaki, Atsuo Maruta, Heiwa Kanamori, Miki Nishimura, Nobuyuki Aotsuka, Kenji Kishi, Shuichi Miyawaki

Research output: Contribution to journalArticle

Abstract

Because of progress in supportive therapies, the upper limit of age for conventional allogenic stem cell transplantation (allo-SCT) is rising. We retrospectively evaluated the impact of age on transplant outcomes in patients older than 50 years of age who underwent conventional allo-SCT in 8 institutions in Japan. The median age was 52-years old (range 50 to 65). The underlying diseases included severe aplastic anemia (n = 3), acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 10), chronic myelogenous leukemia (n = 11), myelodysplastic syndrome (n = 18), and non-Hodgkin lymphoma (n = 3). Forty two patients (67%) with hematological malignancies received allo-SCT in an advanced disease stage at the time of transplant. The two-year overall survival and disease-free survival rate were 50.1% and 43.6%, respectively. In patients with hematological malignancies, the two-year probability rates of survival were 54.3% with standard risk patients, and 45.9% with poor risk patients. The severity of acute GVHD, the kind of grafts, and age (> or = 55) were related to poor prognosis. Our data suggest that prophylaxis of acute GVHD and selection of the graft is more important for older patients, and that patients less than 55-years old can be candidates for conventional allo-SCT.

Original languageEnglish
Pages (from-to)904-910
Number of pages7
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume43
Issue number10
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Transplants
Hematologic Neoplasms
Survival Rate
Aplastic Anemia
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Disease-Free Survival
Japan
Survival

Cite this

Takada, S., Okamoto, S., Sakamaki, H., Maruta, A., Kanamori, H., Nishimura, M., ... Miyawaki, S. (2002). Outcome of allogeneic stem cell transplantation in patients older than 50 years of age. [Rinshō ketsueki] The Japanese journal of clinical hematology, 43(10), 904-910.

Outcome of allogeneic stem cell transplantation in patients older than 50 years of age. / Takada, Satoru; Okamoto, Shinichiro; Sakamaki, Hisashi; Maruta, Atsuo; Kanamori, Heiwa; Nishimura, Miki; Aotsuka, Nobuyuki; Kishi, Kenji; Miyawaki, Shuichi.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 43, No. 10, 2002, p. 904-910.

Research output: Contribution to journalArticle

Takada, S, Okamoto, S, Sakamaki, H, Maruta, A, Kanamori, H, Nishimura, M, Aotsuka, N, Kishi, K & Miyawaki, S 2002, 'Outcome of allogeneic stem cell transplantation in patients older than 50 years of age', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 43, no. 10, pp. 904-910.
Takada, Satoru ; Okamoto, Shinichiro ; Sakamaki, Hisashi ; Maruta, Atsuo ; Kanamori, Heiwa ; Nishimura, Miki ; Aotsuka, Nobuyuki ; Kishi, Kenji ; Miyawaki, Shuichi. / Outcome of allogeneic stem cell transplantation in patients older than 50 years of age. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2002 ; Vol. 43, No. 10. pp. 904-910.
@article{5b9803e9ef8d41ad956583e89b4e50f8,
title = "Outcome of allogeneic stem cell transplantation in patients older than 50 years of age",
abstract = "Because of progress in supportive therapies, the upper limit of age for conventional allogenic stem cell transplantation (allo-SCT) is rising. We retrospectively evaluated the impact of age on transplant outcomes in patients older than 50 years of age who underwent conventional allo-SCT in 8 institutions in Japan. The median age was 52-years old (range 50 to 65). The underlying diseases included severe aplastic anemia (n = 3), acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 10), chronic myelogenous leukemia (n = 11), myelodysplastic syndrome (n = 18), and non-Hodgkin lymphoma (n = 3). Forty two patients (67{\%}) with hematological malignancies received allo-SCT in an advanced disease stage at the time of transplant. The two-year overall survival and disease-free survival rate were 50.1{\%} and 43.6{\%}, respectively. In patients with hematological malignancies, the two-year probability rates of survival were 54.3{\%} with standard risk patients, and 45.9{\%} with poor risk patients. The severity of acute GVHD, the kind of grafts, and age (> or = 55) were related to poor prognosis. Our data suggest that prophylaxis of acute GVHD and selection of the graft is more important for older patients, and that patients less than 55-years old can be candidates for conventional allo-SCT.",
author = "Satoru Takada and Shinichiro Okamoto and Hisashi Sakamaki and Atsuo Maruta and Heiwa Kanamori and Miki Nishimura and Nobuyuki Aotsuka and Kenji Kishi and Shuichi Miyawaki",
year = "2002",
language = "English",
volume = "43",
pages = "904--910",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "10",

}

TY - JOUR

T1 - Outcome of allogeneic stem cell transplantation in patients older than 50 years of age

AU - Takada, Satoru

AU - Okamoto, Shinichiro

AU - Sakamaki, Hisashi

AU - Maruta, Atsuo

AU - Kanamori, Heiwa

AU - Nishimura, Miki

AU - Aotsuka, Nobuyuki

AU - Kishi, Kenji

AU - Miyawaki, Shuichi

PY - 2002

Y1 - 2002

N2 - Because of progress in supportive therapies, the upper limit of age for conventional allogenic stem cell transplantation (allo-SCT) is rising. We retrospectively evaluated the impact of age on transplant outcomes in patients older than 50 years of age who underwent conventional allo-SCT in 8 institutions in Japan. The median age was 52-years old (range 50 to 65). The underlying diseases included severe aplastic anemia (n = 3), acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 10), chronic myelogenous leukemia (n = 11), myelodysplastic syndrome (n = 18), and non-Hodgkin lymphoma (n = 3). Forty two patients (67%) with hematological malignancies received allo-SCT in an advanced disease stage at the time of transplant. The two-year overall survival and disease-free survival rate were 50.1% and 43.6%, respectively. In patients with hematological malignancies, the two-year probability rates of survival were 54.3% with standard risk patients, and 45.9% with poor risk patients. The severity of acute GVHD, the kind of grafts, and age (> or = 55) were related to poor prognosis. Our data suggest that prophylaxis of acute GVHD and selection of the graft is more important for older patients, and that patients less than 55-years old can be candidates for conventional allo-SCT.

AB - Because of progress in supportive therapies, the upper limit of age for conventional allogenic stem cell transplantation (allo-SCT) is rising. We retrospectively evaluated the impact of age on transplant outcomes in patients older than 50 years of age who underwent conventional allo-SCT in 8 institutions in Japan. The median age was 52-years old (range 50 to 65). The underlying diseases included severe aplastic anemia (n = 3), acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 10), chronic myelogenous leukemia (n = 11), myelodysplastic syndrome (n = 18), and non-Hodgkin lymphoma (n = 3). Forty two patients (67%) with hematological malignancies received allo-SCT in an advanced disease stage at the time of transplant. The two-year overall survival and disease-free survival rate were 50.1% and 43.6%, respectively. In patients with hematological malignancies, the two-year probability rates of survival were 54.3% with standard risk patients, and 45.9% with poor risk patients. The severity of acute GVHD, the kind of grafts, and age (> or = 55) were related to poor prognosis. Our data suggest that prophylaxis of acute GVHD and selection of the graft is more important for older patients, and that patients less than 55-years old can be candidates for conventional allo-SCT.

UR - http://www.scopus.com/inward/record.url?scp=0036776936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036776936&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 904

EP - 910

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 10

ER -